Your search returned 11 results.

Results
	1.	Pertuzumab for the treatment of breast cancer: a safety review. [Review] MedStar authors: Swain, Sandra M PMID: 26982349 Year: 2016 Citation: Expert Opinion on Drug Safety. 15(6):853-63, 2016 Jun Institution: Washington Cancer Institute Medline publication type: Journal Article Review Form of publication: Journal Article All authors: Gao J, Swain SM DOI: https://dx.doi.org/10.1517/14740338.2016.1167185 Add to cart (remove)
	2.	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors: Swain, Sandra M PMID: 23475636 Year: 2013 Citation: Oncologist. 18(3):257-64, 2013. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2012-0448 Add to cart (remove)
	3.	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 25693012 Year: 2015 Citation: New England Journal of Medicine. 372(8):724-34, 2015 Feb 19. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1056/NEJMoa1413513 Add to cart (remove)
	4.	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24869931 Year: 2014 Citation: Oncologist. 19(7):693-701, 2014 Jul. Institution: Washington Cancer Institute Form of publication: Journal Article All authors: Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2014-0033 Add to cart (remove)
	5.	Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. [Review] MedStar authors: Swain, Sandra M PMID: 23530718 Year: 2013 Citation: Expert Opinion on Biological Therapy. 13(5):779-90, 2013 May. Institution: Washington Cancer Institute Medline publication type: Journal Article Research Support, Non-U.S. Gov't Review Form of publication: Journal Article All authors: O'Sullivan CC, Swain SM DOI: http://dx.doi.org/10.1517/14712598.2013.783007 Add to cart (remove)
	6.	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 23868905 Year: 2013 Citation: Annals of Oncology. 24(10):2630-5, 2013 Oct. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM DOI: http://dx.doi.org/10.1093/annonc/mdt274 Add to cart (remove)
	7.	Avastin withdrawal symptoms. MedStar authors: Lynce, Filipa Swain, Sandra M PMID: 22263961 Citation: Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb. Institution: Washington Cancer Institute Medline publication type: Editorial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Lynce F, Swain SM DOI: http://dx.doi.org/10.1517/14656566.2012.652088 Add to cart (remove)
	8.	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors: Swain, Sandra M PMID: 22276821 Year: 2012 Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26. Institution: Washington Cancer Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Form of publication: Journal Article All authors: Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1056/NEJMoa1111097 Add to cart (remove)
	9.	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors: Swain, Sandra M PMID: 34890214 Year: 2022 Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10. Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP DOI: https://dx.doi.org/10.1200/JCO.21.00896 Add to cart (remove)
	10.	SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. MedStar authors: Asch, Federico M Barac, Ana Lynce, Filipa Swain, Sandra M PMID: 28314836 Year: 2017 Citation: Oncologist. 22(5):518-525, 2017 May Institution: MedStar Heart & Vascular Institute Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Asch FM, Barac A, Dang C, Isaacs C, Lynce F, Smith KL, Swain SM, Tan MT DOI: https://dx.doi.org/10.1634/theoncologist.2016-0412 Add to cart (remove)
	11.	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors: Asch, Federico M Barac, Ana Cunningham, A Gallagher, Christopher Hofmeyer, Mark Srichai, M B Swain, Sandra M PMID: 30852761 Year: 2019 Citation: Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun. Institution: MedStar Health MedStar Health Research Institute MedStar Heart & Vascular Institute Washington Cancer Institute Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF DOI: https://dx.doi.org/10.1007/s10549-019-05191-2 Add to cart (remove)

Powered by Koha